STOCK TITAN

Structure Therapeutics (GPCR) Stock News, Jun 2023-May 2024

GPCR NASDAQ

Structure Therapeutics Inc. develops oral small-molecule therapeutics for chronic metabolic diseases, with a focus on obesity. The clinical-stage global biopharmaceutical company uses a structure-based drug discovery platform and GPCR-targeted pipeline to advance wholly owned compounds, including aleniglipron, an oral nonpeptide GLP-1 receptor agonist, and ACCG-2671, an oral amylin receptor agonist.

Recurring company updates include clinical data from the ACCESS aleniglipron program, obesity and weight-management research presentations, financial results, research-and-development funding, ADS and warrant financings, and leadership or governance changes. The company’s American depositary shares trade under GPCR, with each ADS representing three ordinary shares.

Rhea-AI Summary

Structure Therapeutics Inc., a biopharmaceutical company, reported financial results for Q1 2024, highlighting upcoming milestones such as data release for obesity drug GSBR-1290 and plans for Phase 2b study. The company aims to address obesity epidemic with its oral small molecule GLP-1 receptor agonist. Positive financial highlights include a cash position of $436.4 million, funding projected operations through 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.82%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.56%
Tags
private placement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.56%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.79%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none

FAQ

What is the current stock price of Structure Therapeutics (GPCR)?

Structure Therapeutics (GPCR) last closed at $16.13.

What is the market cap of Structure Therapeutics (GPCR)?

The market cap of Structure Therapeutics (GPCR) is approximately $1.2B.